We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Invitae Corporation | NYSE:NVTA | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.0891 | 0 | 01:00:00 |
From May 2023 to May 2024
By Ben Glickman
The Food and Drug Administration gave de novo marketing authorization to a diagnostic test that can help detect genes associated with elevated risk of developing cancers.
The FDA said that the test, called the Invitae Common Hereditary Cancers Panel, was an in vitro diagnostic test designed to identify 47 genes which are linked to an elevated risk of cancer.
The de novo premarket review is a regulatory pathway through the FDA for low- to moderate-risk new medical devices.
The FDA said the approval would allow subsequent tests of the same type to go through a potentially quicker and cheaper pre-market process.
Invitae tested over 9,000 samples and found an accuracy greater than or equal to 99%.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
September 29, 2023 19:45 ET (23:45 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Invitae Chart |
1 Month Invitae Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
